title: Oncolytic herpes simplex virus engineering and preparation.
abstract: Herpes simplex virus-1 (HSV-1) is an enveloped, double-stranded DNA virus that has been used with modification as an oncolytic virus against a number of tumor types. Modifications that make HSV-1 replication--conditional, i.e., selectively divide in replicating cells make it fulfill a prerequisite criteria for oncolytic viruses. Other appealing features of HSV-1 as an oncolytic virus include its large, modifiable genome; its sensitivity to antiviral agents, such as ganciclovir; and its lack of host cell integration. Here, we review the methods of HSV-1 engineering, through traditional recombination techniques as well as through bacterial artificial chromosome (BAC) technology. We then describe protocols for titering, amplification, and purification of engineered HSV-1-derived oncolytic viruses.
authors.affiliation: Harvard Medical School, Boston, MA, USA.
authors.forename: Pankaj K
authors.initials: PK
authors.lastname: Agarwalla
authors.forename: Manish K
authors.initials: MK
authors.lastname: Aghi
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology; D022202:Chromosomes, Artificial, Bacterial / Q000235:genetics; D015774:Ganciclovir / Q000494:pharmacology; D005818:Genetic Engineering / Q000379:methods*; D005822:Genetic Vectors; D018259:Herpesvirus 1, Human / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D011995:Recombination, Genetic / Q000235:genetics; D014779:Virus Replication / Q000235:genetics*
chemical_list: D000998:Antiviral Agents; D015774:Ganciclovir